Cytek Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We currently lease approximately 99,000 square feet of office and laboratory space for our headquarters in Fremont, California. The lease expires in February 2029.
In Wuxi, China, we lease approximately 9,800 square feet of manufacturing and office space. The lease expires in January 2027. In November 2023, we purchased a building in Wuxi, China and relocated our Wuxi operations to the new facility in January 2024. The Wuxi building has approximately 56,000 square feet of manufacturing and office space.
In Shanghai, China, we lease approximately 14,000 square feet of office and laboratory space, under multiple leases expiring between October 2026 and November 2027.
In Singapore, we lease approximately 8,500 square feet of manufacturing and office space. The lease expires in January 2028.
We also lease space in Seattle, Washington; Bethesda, Maryland; San Diego, California; Beijing, China; Tokyo, Japan; Amsterdam, Netherlands; and Ely, England. We believe that our existing office, laboratory and manufacturing space, together with additional space and facilities available on commercially reasonable terms, will be sufficient to meet our current and future needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.